Editas Medicine (EDIT) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Strategic vision and priorities

• Focused on three pillars: advancing Rene-cel to approval, building a differentiated in vivo discovery pipeline, and leveraging foundational IP through out-licensing and monetization.

• Innovation is driven by the goal of high patient impact, not novelty for its own sake.

• Capital is methodically allocated, prioritizing Rene-cel due to its registrational study and potential approval, while also investing in in vivo programs.

• Open to partnering Rene-cel, especially for markets outside the US, if terms maximize value for shareholders and patients.

Technology differentiation and capabilities

• Utilizes the unique AsCas12a enzyme, offering high editing efficiency and fidelity with minimal off-target effects, validated clinically.

• Substantial expertise in guide RNA chemistry, enzymology, and computational biology, with tools widely used in academia and industry.

• Developed robust development and CMC organizations over the past two years.

In vivo and ex vivo therapeutic strategies

• In vivo strategy centers on functional upregulation of compensatory proteins, diverging from the common knockdown approach.

• Proven ex vivo upregulation of gamma globin for sickle cell and thalassemia, now expanding to in vivo applications across multiple tissues.

• Targeting extrahepatic tissues using modified LNPs to avoid the liver and direct therapies to specific cells.